Publications by authors named "M Bollet"
Complementary and integrative medicine (CIM) encompasses over 400 modalities, according to the World Health Organization (WHO). In 2011, 70% of the European Union's population reported having used CIM at least once, with 25% using it annually. This study examines the engagement, motivations, and satisfaction of users in the French health care system through data from Medoucine, France's largest online platform for complementary therapies.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare patient preferences for administering pegfilgrastim, a medication used to prevent chemotherapy-induced neutropenia, via prefilled syringe versus pen device among cancer patients at the Rafael Institute in France.
- In the trial involving 150 patients, results showed a significant preference for the pen device, with participants reporting lower pain levels and more positive emotions compared to the syringe, although satisfaction with nursing care was higher with the syringe.
- Overall, the findings highlighted a stronger preference for using the pen device for administration, which can help shape clinical practices and enhance patient-centered care.
Radiation therapy is a corner stone of breast cancer treatment as it has been shown postoperatively that it improves local control and overall survival. In recent years, multidisciplinary therapeutic strategies have evolved considerably for early-stage breast cancer, both surgically and in terms of systemic treatments or radiation therapy. Each of these developments affects other treatment components and open up new questions allowing even more personalized treatments.
View Article and Find Full Text PDFPurpose: Treatment options for renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC-TT) are limited and carry substantial risks. Currently, there are no standard treatment options in the setting of recurrent or unresectable RCC with IVC-TT.
Methods: We report our experience of treating an IVC-TT RCC patient with stereotactic body radiation therapy (SBRT).
Background: Neoadjuvant fluoropyrimidine (5FU or capecitabine)-based chemoradiotherapy (CRT) has been considered the standard of care for locally advanced rectal cancer (LARC). Whether addition of oxaliplatin (OXP) will further improve clinical outcomes is still unclear.
Methods: To identify clinical trials combining oxaliplatin in preoperative CRT or perioperative chemotherapy for LARC published until March 2021, we searched PubMed and the Cochrane Library.